PIK@CA mutations do not have clinical validity to predict intrinsic resistance to adjuvant tamoxifen and may therefore be unsuitable as companion diagnostic for PI@K/AKT/mTOR inhibitors in ER - positive , postmenopausal , early breast cancer patients .